Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide and Temodar in Metastatic Neuroendocrine Tumors
NCT00165230Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2002
- Primary completion
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide in Neuroendocrine Neoplasm (NEN), sponsored by Dana-Farber Cancer Institute. Started May 2002; status: completed.
02
Drugs
thalidomide
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00165230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00165230.